Compare Marvell Technology Inc (MRVL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs BIO-TECHNE Corp — how do they compare? Marvell Technology Inc trades at $216.55 (market cap $187.19B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Marvell Technology Inc is far larger — about 16.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| MRVL | TECH | |
|---|---|---|
Market Cap | $187.19B | $11.24B |
Sector | Technology | Health |
52-Week High | $316.43 | $72.29 |
52-Week Low | $62.31 | $43.31 |
Enterprise Value | $188.63B | $11.32B |
Dividend Yield | 0.12% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRVL trades at $218.72, up 3.89% today, with a bullish technical signal from moving averages but neutral oscillators. The stock has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.928. Revenue grew to $5.77B in 2025, though net income was negative. Analyst consensus is strongly bullish with an 82% buy rating and a $275.68 price target, implying 26% upside. Recent news highlights AI infrastructure product launches and institutional buying interest.
Outlook is positive driven by AI growth and earnings momentum, but high valuation multiples (P/E 75.16) and geopolitical risks from U.S.-China trade tensions pose challenges. Cash flow trends show improvement, with 2026 net cash flow projected at $3.0B. Investors should weigh strong analyst support against margin pressures and competitive threats in the semiconductor sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
